View Future GrowthAstellas Pharma 過去の業績過去 基準チェック /56Astellas Pharmaは、平均年間4.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間10.3% 11.3%収益成長率で 成長しています。 Astellas Pharmaの自己資本利益率は15.9%であり、純利益率は13.6%です。主要情報4.49%収益成長率5.57%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率11.25%株主資本利益率15.93%ネット・マージン13.63%前回の決算情報31 Mar 2026最近の業績更新Astellas Pharma Inc. to Report Fiscal Year 2026 Results on Apr 27, 2026Apr 04Astellas Pharma Inc. to Report Q3, 2026 Results on Feb 04, 2026Jan 10Astellas Pharma Inc. to Report Q2, 2026 Results on Oct 30, 2025Oct 08Astellas Pharma Inc. to Report Q1, 2026 Results on Jul 30, 2025Jul 11Astellas Pharma Inc. to Report Fiscal Year 2025 Results on Apr 25, 2025Apr 03Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025Jan 03すべての更新を表示Recent updatesAstellas Pharma Inc., Annual General Meeting, Jun 19, 2026Apr 27Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20Astellas Pharma Inc. to Report Fiscal Year 2026 Results on Apr 27, 2026Apr 04Astellas Pharma Inc. and Hovon Foundation Confirm Phase 3 Study Results for Xospata (Gilteritinib) in Newly Diagnosed FLT3m+ AMLMar 10Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28Astellas Pharma Inc. Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent LitigationFeb 12Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026Feb 05Astellas Pharma Inc. to Report Q3, 2026 Results on Feb 04, 2026Jan 10Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder CancerNov 22Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026Oct 30Astellas Pharma Inc. Presents Preliminary Real-World Veozah (Fezolinetant) Data from Option-Vms Phase Iv Observational StudyOct 22+ 1 more updateAstellas Pharma Inc. Announces First Results from the Open-Label Extension Trial of the Phase 3 GATHER2 StudyOct 20+ 1 more updateAstellas Pharma Inc. Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic CancerOct 14Astellas Pharma Inc. to Report Q2, 2026 Results on Oct 30, 2025Oct 08Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer Is Now Funded in Both Ontario and QuebecOct 02Astellas Pharma Inc. to Present Pioneering Advances Across Its Portfolio and Pipeline At Esmo 2025Oct 01Astellas Pharma Inc. Announces Resignation of Nick Eshkenazi, Current Chief Digital & Transformation Officer, Effective September 30, 2025Sep 30Astellas Pharma Inc. Announces Japanese Ministry of Health, Labor and Welfare Grants Conditional Approval of IZERVAY for Suppression of Geographic Atrophy Growth in Atrophic Age-Related Macular DegenerationSep 19PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12Astellas Pharma Inc. to Report Q1, 2026 Results on Jul 30, 2025Jul 11Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10Astellas Pharma Canada, Inc. Announces That XTANDI®? (enzalutamide) Now Funded in Ontario for All Approved Prostate Cancer IndicationsJun 27Astellas Pharma Inc. and Pfizer Inc. Announces Long-Term Overall Survival in Metastatic Hormone-S sensitive Prostate CancerMay 23Astellas Pharma Inc. Presents New Data That Explores Potential of Its Cancer Therapies At 2025 Asco Annual MeetingMay 20Astellas engages with FarallonMay 08Astellas Pharma Inc., Annual General Meeting, Jun 19, 2025Apr 25Astellas Pharma Inc. to Report Fiscal Year 2025 Results on Apr 25, 2025Apr 03U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyFeb 13Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in JapanFeb 05Astellas Pharma Inc. Announces Management Changes, Effective April 1, 2025Feb 04Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerJan 09+ 1 more updateAstellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder CancerJan 08China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction AdenocarcinomaJan 06Astellas Pharma Inc. to Report Q3, 2025 Results on Feb 04, 2025Jan 03Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej CancerOct 19Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024Oct 05Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerSep 24Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause SocietySep 04European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial CancerAug 28Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine TherapyAug 27Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial CancerAug 20Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction CancerJul 27+ 1 more updateAstellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024Jun 29U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action DateMay 31Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024Apr 26+ 1 more updateAstellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingApr 25Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024Apr 13+ 1 more updateAstellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024Apr 03U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic AtrophyApr 02China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerMar 28Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric CancerMar 27Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment SettingMar 22Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in JapanMar 05Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDAFeb 16Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder CancerJan 31European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerJan 27Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.SJan 09Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024Dec 28Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged ChildrenDec 18Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)Dec 16Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with MenopauseDec 11Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive MucormycosisDec 09Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder CancerDec 02Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone TherapyNov 30Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment SettingNov 17Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus ChemotherapyOct 24Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023Oct 16Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)Oct 14Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023Sep 28Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical TrialSep 23Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate CancerSep 20+ 1 more updateAstellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAYSep 19European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical RecurrenceSep 13Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).Aug 30FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical RecurrenceAug 24Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad PegolAug 18U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in ChildrenAug 11Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical TrialsAug 09Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023Aug 03China's National Medical Products Administration Accepts Astellas' Biologics License Application for ZolbetuximabAug 01European Medicines Agency Accepts Astellas' Marketing Authorization Application for ZolbetuximabJul 14Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023Jul 12Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License ApplicationJul 06Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for FezolinetantJun 28Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent TrialJun 12Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for ZolbetuximabJun 09Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to MenopauseMay 17Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.SFeb 20Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Feb 07+ 1 more updateAstellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023Feb 06収支内訳Astellas Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ALPM.F 収益、費用、利益 ( )JPY Millions日付収益収益G+A経費研究開発費31 Mar 262,139,245291,535860,312314,82731 Dec 252,043,974294,481843,389305,28730 Sep 252,006,816124,871840,455298,61030 Jun 251,944,99381,566833,152312,52831 Mar 251,912,32350,747843,032327,65131 Dec 241,867,631-57,427821,251329,27530 Sep 241,772,15554,746799,059324,57030 Jun 241,701,80621,519775,191316,41631 Mar 241,603,67217,045740,110294,18731 Dec 231,543,3244,198706,256286,41030 Sep 231,523,57238,090669,778278,89830 Jun 231,511,818107,031645,058266,71331 Mar 231,518,61998,714630,272276,12831 Dec 221,468,235136,430613,397274,41430 Sep 221,406,682148,911586,290266,12730 Jun 221,351,811118,211565,127261,70431 Mar 221,296,163124,086548,840246,01031 Dec 211,300,914120,167547,692233,31630 Sep 211,285,714119,360532,687231,84930 Jun 211,268,702100,863520,649225,51431 Mar 211,249,528120,589504,316224,48931 Dec 201,253,215138,307508,764233,29330 Sep 201,265,853139,722515,363230,95230 Jun 201,273,678187,306502,601228,00731 Mar 201,300,843195,411499,295224,22631 Dec 191,289,855220,751488,054218,47730 Sep 191,309,722246,925484,800214,09030 Jun 191,311,397226,224494,845210,05731 Mar 191,306,348222,265490,263208,68231 Dec 181,305,901213,600484,099209,11730 Sep 181,307,658186,429481,546212,86730 Jun 181,306,830176,770478,883216,43631 Mar 181,300,316164,679478,330220,78131 Dec 171,305,521182,515484,126221,46330 Sep 171,299,746185,754478,249215,93830 Jun 171,296,484194,556471,227213,58431 Mar 171,311,665218,701470,777208,12931 Dec 161,312,627207,940474,335208,95830 Sep 161,336,878205,818481,460213,29530 Jun 161,366,799215,678493,582220,70731 Mar 161,372,706193,687500,359225,66531 Dec 151,360,153185,659497,984223,59030 Sep 151,340,307168,805490,493221,60830 Jun 151,295,761144,617474,276214,931質の高い収益: ALPM.Fは 高品質の収益 を持っています。利益率の向上: ALPM.Fの現在の純利益率 (13.6%)は、昨年(2.7%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ALPM.Fの収益は過去 5 年間で年間4.5%増加しました。成長の加速: ALPM.Fの過去 1 年間の収益成長率 ( 474.5% ) は、5 年間の平均 ( 年間4.5%を上回っています。収益対業界: ALPM.Fの過去 1 年間の収益成長率 ( 474.5% ) はPharmaceuticals業界-3.2%を上回りました。株主資本利益率高いROE: ALPM.Fの 自己資本利益率 ( 15.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 22:57終値2026/05/01 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Astellas Pharma Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research21 その他のアナリストを表示
Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20
Astellas Pharma Inc. and Hovon Foundation Confirm Phase 3 Study Results for Xospata (Gilteritinib) in Newly Diagnosed FLT3m+ AMLMar 10
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28
Astellas Pharma Inc. Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent LitigationFeb 12
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026Feb 05
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year Ending March 31, 2026Oct 30
Astellas Pharma Inc. Presents Preliminary Real-World Veozah (Fezolinetant) Data from Option-Vms Phase Iv Observational StudyOct 22+ 1 more update
Astellas Pharma Inc. Announces First Results from the Open-Label Extension Trial of the Phase 3 GATHER2 StudyOct 20+ 1 more update
Astellas Pharma Inc. Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic CancerOct 14
Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer Is Now Funded in Both Ontario and QuebecOct 02
Astellas Pharma Inc. to Present Pioneering Advances Across Its Portfolio and Pipeline At Esmo 2025Oct 01
Astellas Pharma Inc. Announces Resignation of Nick Eshkenazi, Current Chief Digital & Transformation Officer, Effective September 30, 2025Sep 30
Astellas Pharma Inc. Announces Japanese Ministry of Health, Labor and Welfare Grants Conditional Approval of IZERVAY for Suppression of Geographic Atrophy Growth in Atrophic Age-Related Macular DegenerationSep 19
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10
Astellas Pharma Canada, Inc. Announces That XTANDI®? (enzalutamide) Now Funded in Ontario for All Approved Prostate Cancer IndicationsJun 27
Astellas Pharma Inc. and Pfizer Inc. Announces Long-Term Overall Survival in Metastatic Hormone-S sensitive Prostate CancerMay 23
Astellas Pharma Inc. Presents New Data That Explores Potential of Its Cancer Therapies At 2025 Asco Annual MeetingMay 20
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyFeb 13
Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11
Astellas Pharma Inc. Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in JapanFeb 05
Astellas Receives Health Canada Approval for Vyloy® (Zolbetuximab) in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerJan 09+ 1 more update
Astellas Pharma Inc. Announces China's National Medical Products Administration (Nmpa) Approves Padcev™ in Combination with Keytruda® (Pembrolizumab) for the Treatment of Advanced Bladder CancerJan 08
China's National Medical Products Administration Approves Vyloy (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction AdenocarcinomaJan 06
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej CancerOct 19
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction CancerSep 24
Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause SocietySep 04
European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial CancerAug 28
Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine TherapyAug 27
Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial CancerAug 20
Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction CancerJul 27+ 1 more update
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action DateMay 31
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingApr 25
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024Apr 13+ 1 more update
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic AtrophyApr 02
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerMar 28
Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric CancerMar 27
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment SettingMar 22
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in JapanMar 05
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDAFeb 16
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder CancerJan 31
European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerJan 27
Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged ChildrenDec 18
Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)Dec 16
Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with MenopauseDec 11
Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive MucormycosisDec 09
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder CancerDec 02
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone TherapyNov 30
Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus ChemotherapyOct 24
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical TrialSep 23
Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate CancerSep 20+ 1 more update
Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAYSep 19
European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical RecurrenceSep 13
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).Aug 30
FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical RecurrenceAug 24
Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad PegolAug 18
U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in ChildrenAug 11
Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical TrialsAug 09
Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023Aug 03
China's National Medical Products Administration Accepts Astellas' Biologics License Application for ZolbetuximabAug 01
European Medicines Agency Accepts Astellas' Marketing Authorization Application for ZolbetuximabJul 14
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License ApplicationJul 06
Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for FezolinetantJun 28
Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent TrialJun 12
Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for ZolbetuximabJun 09
Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to MenopauseMay 17
Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Feb 07+ 1 more update